Related Experiment Videos
Evaluation of a slow-release lithium carbonate formulation
The American Journal of Psychiatry
|August 1, 1978
Summary
This study compared slow-release lithium with standard formulations. While initial tests suggested differences, both forms demonstrated equal bioavailability, with the slow-release version reducing plasma lithium level variability by 50%.
Area of Science:
- Pharmacokinetics
- Drug formulation
- Lithium therapy
Background:
- Lithium is a common mood stabilizer for bipolar disorder.
- Standard lithium formulations can have variable plasma levels.
- Slow-release formulations aim to improve lithium's pharmacokinetic profile.
Purpose of the Study:
- To compare the pharmacokinetic profiles of a slow-release lithium preparation against a standard formulation.
- To assess the bioavailability and plasma level variability of both lithium formulations in healthy volunteers and patients.
Main Methods:
- Single-dose pharmacokinetic analysis in normal volunteers.
- Steady-state pharmacokinetic analysis (b.i.d. dosing) in normal volunteers and patients.
- Comparison of plasma lithium levels and area under the curve (AUC).
Main Results:
- Initial single-dose data suggested non-bioequivalence between formulations.
- Area under the curve (AUC) was similar for both forms, indicating equal bioavailability.
- Slow-release lithium decreased postdose plasma lithium level variability by up to 50% in patients.
Conclusions:
- Despite initial indications, slow-release lithium demonstrates comparable bioavailability to standard formulations.
- The slow-release lithium preparation offers reduced plasma lithium level fluctuations.
- This improved pharmacokinetic profile may enhance therapeutic efficacy and patient compliance in lithium treatment.